Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
Johnson and Johnson
Baxter
AstraZeneca

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR RYDAPT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rydapt

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01830361 ↗ Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML Completed Novartis Pharmaceuticals Phase 2 2013-03-13 To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT01830361 ↗ Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML Completed Technische Universität Dresden Phase 2 2013-03-13 To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT02115295 ↗ Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Recruiting National Cancer Institute (NCI) Phase 2 2014-05-19 This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT02115295 ↗ Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Recruiting M.D. Anderson Cancer Center Phase 2 2014-05-19 This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT02723435 ↗ Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant Withdrawn National Cancer Institute (NCI) Phase 2 1969-12-31 This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.
NCT02723435 ↗ Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant Withdrawn Stanford University Phase 2 1969-12-31 This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rydapt

Condition Name

Condition Name for Rydapt
Intervention Trials
Acute Myeloid Leukemia 10
Untreated Adult Acute Myeloid Leukemia 2
Myelodysplastic Syndrome 2
Myelodysplastic Syndrome With Excess Blasts-2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rydapt
Intervention Trials
Leukemia, Myeloid, Acute 11
Leukemia, Myeloid 11
Leukemia 10
Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rydapt

Trials by Country

Trials by Country for Rydapt
Location Trials
United States 82
Germany 5
Netherlands 2
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rydapt
Location Trials
California 4
Florida 4
North Carolina 3
New Jersey 3
Nebraska 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rydapt

Clinical Trial Phase

Clinical Trial Phase for Rydapt
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rydapt
Clinical Trial Phase Trials
Recruiting 5
Active, not recruiting 2
Withdrawn 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rydapt

Sponsor Name

Sponsor Name for Rydapt
Sponsor Trials
National Cancer Institute (NCI) 3
Novartis Pharmaceuticals 3
Technische Universität Dresden 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rydapt
Sponsor Trials
Other 14
Industry 9
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKinsey
Medtronic
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.